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Purpose: Side effects and side-effect risk information can be provided using written medicine 
information. However, challenges exist in effectively communicating this information to consum-
ers. This study aimed to explore broad consumer profiles relevant to ramipril and clopidogrel 
side-effect risk information interpretation.
Methods: Three focus groups were conducted (n=18 consumers) exploring consumer perspec-
tives, understanding and treatment decision making in response to ramipril and clopidogrel 
written medicine information leaflets containing side effects and side-effect risk information. 
All discussions were audio recorded, transcribed verbatim, and analyzed to explore consumer 
profiles pertaining to side-effect risk appraisal.
Results: Three consumer profiles emerged: glass half-empty, glass half-full, and middle-of-the-
road consumers, highlighting the influence of perceived individual susceptibility, interpretation 
of side-effect risk information, and interindividual differences, on consumers’ understanding of 
side-effect risk information. All profiles emphasized the importance of gaining an understanding 
of individual side-effect risk when taking medicines.
Conclusion: Written side-effect risk information is not interpreted uniformly by consumers. 
Consumers formulated their own construct of individual susceptibility to side effects. Health 
care professionals should consider how consumers interpret side-effect risk information and its 
impact on medication use. Existing risk communication strategies should be evaluated in light 
of these profiles to determine their effectiveness in conveying information.
Keywords: adverse effects, risk assessment, drug labeling, consumer participation, 
comprehension
Introduction
Consumers desire information regarding the risk of medication side effects.1,2 The 
complexity of communicating this type of information to consumers is apparent from 
both medicine information development and consumer perspectives. The process relies 
on obtaining relevant and accurate risk data and effectively communicating these data 
to consumers to facilitate understanding of the risks associated with their medicines. 
Different approaches to communicating side-effect risk information can also influence 
consumer interpretation of risk and views about a medicine,3 potentially impacting 
medication use and patient safety.
Written medicine information (WMI), in the form of patient information leaflets, 
is an important information source for consumers and a useful avenue through which 
side-effect risk information can be conveyed. Different side-effect risk communication 
strategies for WMI have encompassed various recommendations over time. These 
include verbal descriptors (such as “common” or “rare”) advocated for use by the 
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European Commission,4 which have been shown to lead to 
consumer misunderstanding of medication risks,5,6 and the 
updated UK guidelines that provide detailed recommenda-
tions, such as only using verbal descriptors together with 
relevant numerical risk information (such as “common” – 
may affect up to one in ten people), and strategies to help 
minimize consumer misinterpretation when communicating 
side-effect risk information.7
In Australia, WMI (known as Consumer Medicine 
Information [CMI]) leaflets must be legally available for all 
prescription medicines and a proportion of nonprescription 
medicines (nonprescription medicines that must be handed 
out by the pharmacist).8 As part of the legislation outlining 
the requirements for CMI content, side-effect information 
must be included along with any necessary actions to take 
if side effects occur.9 However, similar to other international 
regulatory contexts, there is no legal requirement for numeri-
cal side-effect risk information to be included in WMI, which 
may present a potential for a mismatch between consumer 
information needs and WMI content.10 This lack of infor-
mation communicated to consumers may also impact their 
medication side-effect risk appraisal processes.
Previous work has demonstrated inconsistency in con-
sumers’ understanding of terms used to communicate side-
effect information in WMI.11 Numerical side-effect risk 
information presentation (percentages or natural frequencies) 
and framing (positive or negative) had some influence on con-
sumer risk appraisal processes.11 Despite consumers being the 
target population for which WMI is developed, there has been 
limited work to date that specifically examines interpersonal 
variation in the interpretation of side-effect risk information 
included in WMI. In this paper, we examine this type of 
variability in an Australian context and identify different 
consumer profiles that may help explain this variability.
Material and methods
This paper analyzes data collected as part of a previous study11 
that investigated consumer opinions on side-effect informa-
tion presentation in both existing Australian CMI leaflets and 
researcher-developed WMI for ramipril and clopidogrel and 
explored their understanding of the likelihood and severity 
of potential side effects. As part of the study, CMI leaflets 
for ramipril and clopidogrel were revised11 with the support 
of good information design, functional linguistics, and medi-
cine information expertise.10 In particular, relevant psycho-
logical theories (fuzzy trace theory,12,13 affect heuristic,14–16 
frequency hypothesis,12 and cognitive-experiential17) were 
applied to support the written communication of side-effect 
risk information in the revised WMI. Four alternative WMI 
leaflet versions were developed, with changes made to the 
side effects’ section (a detailed outline of the development 
process has been published previously).11 Version 1 did not 
include any numerical side-effect risk information; how-
ever, the side effects were presented using tables. Version 2 
included positively framed numerical side-effect risk infor-
mation (likelihood of not experiencing the side effect[s]), 
communicated using percentages, and benefit information 
of taking the medicine. Version 3 was the same as Version 2 
minus the benefit information. Version 4 included negatively 
framed numerical side-effect risk information (likelihood of 
experiencing the side effect[s]), communicated using natural 
frequencies.
Three focus groups (Sydney, Australia) were conducted 
with 18 consumers in total as part of the qualitative explo-
ration to address the research aims.11 Thematic or data 
saturation was achieved,18 as discussed and agreed upon by 
members of the research team in relation to the study objec-
tives, and no further focus groups were conducted. Recruit-
ment was conducted by a market research company using a 
recruitment brief provided by the researchers. Participants 
were eligible to participate in the study if they were:
·	 $50 years
·	 Taking one prescription medicine or more, or had done 
so in the 6 months prior to participation in the study
·	 Conversant in English
·	 Not taking ramipril or clopidogrel at the time of the 
study.
The existing Australian CMI leaflets were provided to 
consumers in advance of the focus groups, and redeveloped 
WMI leaflets were provided as stimulus material to consum-
ers during the focus groups for discussion about their perspec-
tives, interpretation of information, and impact on treatment 
decision making and intention to take the medication, in light 
of the available WMI leaflets, using a semistructured focus 
group protocol developed by the researchers. Consumers’ 
interpretation of side-effect risks was explored in more detail. 
The focus of this paper is on the interpersonal differences, 
consumer risk appraisal patterns, and their implications for 
WMI development.
All focus group discussions were audio recorded, with 
consent obtained from the participants, and transcribed ver-
batim. The data were analyzed to explore consumer profiles 
specifically in the context of side-effect risk information 
interpretation. Verification of all transcripts was completed 
against the corresponding audio recording for accuracy prior 
to data analysis. Data analysis was conducted independently 
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by two researchers (PA and VT) for validity purposes, and 
the content was thematically analyzed.19 Each researcher 
analyzed the transcripts independently by hand, where sub-
themes relating to variability in side-effect risk information 
interpretation were identified inductively. The findings of the 
independent data analysis were then discussed, consolidated, 
and agreed upon within the research team. This synthesis 
formed the basis of the identification of the broad consumer 
profiles presented in this paper. Ethics approval for the study 
was granted by the University of Sydney Human Research 
Ethics Committee.
Results
A total of nine females and nine males participated in the 
study, aged between 50 years and 65 years (mean 58 years). 
The majority were born in Australia, with English the pre-
dominant language spoken at home. The highest level of 
education completed by most participants was reported as 
the Higher School Certificate (year 12) or below (such as the 
School Certificate [year 10] or primary school [year 6]).
There was considerable variability among focus group 
participants in how they interpreted the side-effect risk 
information provided in the leaflets. Three primary profiles 
emerged from the data: 1) glass half-empty consumers, 
2) glass half-full consumers, and 3) middle-of-the-road 
consumers. The characteristics associated with each profile 
are described below together with illustrative quotes and are 
summarized in Table 1.
glass half-empty consumers
Glass half-empty consumers perceived themselves to be at 
an increased risk of experiencing medication side effects 
or displayed apprehension toward specific side-effect risks 
which impacted their stated likelihood of using the medica-
tion if, for instance, their doctor prescribed it for them.
As I was reading this, that’s the first thing I thought. If my 
doctor says “I’m going to put you on this”, I [would] go 
“no, you’re not” because I’ve read the pamphlet [existing 
Australian CMI without numerical information] mate and 
I don’t think it’s a good risk, because there is too much. 
There is too much that can happen. [focus group 2 (FG2); 
male 1 (M1)].
I think that’s overwhelming. I’d look at that and think 
“I’m not taking that”. [FG3; female 1 (F1)].
Past experience of side effects led to heightened perceived 
individual risk of experiencing side effects, where wariness 
was evident in light of previous side effects experienced by, 
for example, a family member. Consumer perceptions of their 
own individual risk in many respects overruled the numerical 
risk information and/or how the information was framed.
Yeah [I would] most probably get them. [My daughter] 
would get them. [FG2F1].
The magnitude of risk made little difference to glass half-
empty consumers. For example, even side effects classified 
as “very rare” and having a likelihood of 1 in 10,000 were 
still large enough for a glass half-empty consumer to say they 
would be dissuaded from taking the study medicine.
glass half-full consumers
Glass half-full consumers were largely confident that they 
would not experience side effects or had a more favorable 
view of the benefit–risk profile of the medicine. Decreased 
perceived individual risk played a role in leading this posi-
tive outlook.
I’m optimistic and I don’t count myself as the one in the 
hundred [who experience the side effect]. [FG3F2].
Consumers utilized and interpreted positively framed 
side-effect information (eg, likelihood of not experiencing 
Table 1 Summary of the core characteristics of the identified consumer profiles
Profile Description of core characteristics
glass half-empty consumers considers themselves as part of the group who will experience the medication side effect(s)
Perceived medication risks outweigh the potential benefits, which then affect projected 
intention to take the medication
heightened perceived individual risk takes precedence
glass half-full consumers Generally confident that they would not experience the medication side effect(s)
Perceived individual risk lower
Perceived favorable benefit–risk profile for the medicine
Middle-of-the-road consumers cannot ascertain their own likelihood of experiencing side effect(s) after reading the 
information
Focused primarily on individual risk rather than the numerical information presented
Trust in the prescribing doctor overrides the need to determine the risk of experiencing 
medication side effect(s)
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the side effect is 99%) and benefit information included in 
WMI (when noticed) together with risk information to help 
establish their own perceived benefit–risk profile for the 
medicine.
What you’re saying here is these are the side effects that 
could happen and you could get all of them or none of them 
and at the end of the day it’s going to do more good than it’s 
going to do harm. You’d definitely take them. [FG1M3].
Middle-of-the-road consumers
Middle-of-the-road consumers were unable to ascertain the 
likelihood of experiencing a side effect after reading informa-
tion about the medication. For instance, when asked what the 
numerical side-effect risk information meant, one participant 
said: Nothing, it means nothing to me. [FG1F2].
A large contributor to this was consumers’ focus on 
determining their own individual risk.
I think generally, if you do feel that and you know your body 
reasonably well then, if it’s serious you’ll feel something 
and you know if it’s happened since you’ve been taking 
this. My best thing is my body telling me that this is not 
working for me. [FG1F2].
Despite reading the information, some consumers disre-
garded numerical side-effect risk information because they 
believed that true likelihood was not being conveyed, that 
numerical information did not equate to the necessary action 
required to be taken if a side effect was experienced, or because 
they could not interpret and apply the numerical information.
If I experience anything I’m not going to worry about what 
number out of a hundred. I’m going to go to my doctor to 
work it out. I don’t want to be worried about percentages 
or anything. [FG1F2].
Some felt that the presented numerical side-effect risk 
information could not be completely trusted:
No. Not even the doctor knows himself. [FG2F2].
They are just a guide. [FG2M1].
Consumers also discussed the notion of trust in the 
doctor prescribing the medication, where, for example, it 
negated the need to ascertain the risk of experiencing side 
effects.
As far as I’m concerned, if I need to take that then that’s 
what I need to take because the doctor said I should take 
it. It doesn’t matter if there’s a chance of it killing me or a 
chance of it making me ill. [FG3M2].
Discussion
Overall, three profiles were identified based on how consum-
ers understood and interpreted side-effect information. These 
profiles represented a spectrum of consumer perceptions 
about their likelihood of experiencing side effects. Individual 
risk was the core focus for many consumers. When making 
decisions about medication use, consumers relied heavily on 
perceptions of individual susceptibility and were influenced 
by their own traits, experience, and how side-effect informa-
tion was understood. Moreover, some wanted more informa-
tion about the test population from which the numerical risk 
data were determined such as its sample size, as previously 
reported with this group of participants.11 This could then 
possibly allow consumers to better relate this information to 
their own risk and to ascertain the relevance of these data to 
their personal susceptibility of experiencing medication side 
effects. This is in line with social comparison theory, which 
posits that people often assess themselves via comparison 
with similar others.20 The lack of this information in the WMI 
leaflets may account for why some participants had difficulty 
in interpreting the numerical risk information.
Several factors were found to underpin the application of 
side-effect risk information to the consumer’s own situation. 
These included an accurate understanding and interpretation 
of the information, an understanding of general risk infor-
mation, susceptibility to positive framing effects (similarly 
identified in previous work),21 and personal characteristics 
and skills. These factors highlight the role of a learned 
intermediary in assisting to interpret and personalize side-
effect information. Another future consideration would be 
the potential for tailored WMI;22 however, the feasibility of 
such a strategy requires further exploration. With the absence 
of a single effective approach to adopt when communicating 
side-effect risk information in WMI, which would facilitate 
appropriate risk understanding for all consumers, learned 
intermediaries such as pharmacists and doctors remain the 
key link in tailoring information for each consumer, particu-
larly when taking into account overarching differences in 
health literacy and/or numeracy levels between consumers 
across all profiles. Spoken information provided to comple-
ment WMI could help all consumers, in particular middle-
of-the-road consumers, to better understand the treatment 
rationale and potential benefits and risks associated with 
medication use. Consequently, as with WMI, attention should 
be paid to how spoken information is expressed or framed to 
help better facilitate informed treatment decision making.
Limitations exist in the side-effect risk data available and 
transparency of numerical reporting to consumers via WMI. 
Thus, varied approaches adopted by medicine information 
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developers when communicating side-effect risk may have 
varying impacts on the broad consumer profiles identified 
and the interpretation of information by consumers. For 
glass half-empty consumers, the inclusion of useful benefit 
information in WMI may allow for more balanced under-
standing of treatment expectations, when conveyed alongside 
numerical side-effect risk information, clear indications 
of side-effect severity, and actions required to be taken if 
side effects are experienced. Hamrosi et al also found that 
consumers generally viewed broad benefit information in 
WMI favorably, where it acted as a motivator for medica-
tion use.23 However, more importantly, benefit information 
should be responsibly communicated alongside side-effect 
risk information to help ensure that treatment benefits are 
not amplified by glass half-full consumers. Additionally, 
further exploration is needed in order to work in partner-
ship with middle-of-the-road consumers to find better 
strategies to convey available side-effect risk information 
in a more meaningful way. There is also the possibility that 
these individual differences in medication risk information 
interpretation may not be stable across all medications for 
all medical conditions, particularly in light of other factors 
such as self-perceived health status. Therefore, these three 
profiles are not necessarily mutually exclusive for a single 
given patient at different time points across different medi-
cines being used.
The three consumer profiles illustrate identified patterns 
in consumers’ approach, perceived relevance, and appraisal 
of communicated written side-effect risk information. 
Together with the previously published findings11 from 
this study (consumer perspectives of the WMI leaflets and 
the impact of how side-effect risk information was com-
municated on consumer understanding of this information), 
communicators of risk information (whether verbal or writ-
ten) may find these findings useful to consider in an attempt 
to minimize a potential disconnect between the intended 
versus actual usefulness of side-effect risk information to 
consumers. However, there are study limitations that should 
be acknowledged. The choice of exemplar study medicines 
ramipril and clopidogrel may have introduced a medicine 
bias and potentially affected consumers’ interpretation of 
the information, and thus, the profiles identified. It may also 
have been useful to explore the usability of the WMI leaflets 
initially, prior to their use as stimulus material in the focus 
groups, to help map these focus group findings against leaflet 
usability data. This is critical as the next step if the inclusion 
of similar side-effect risk information in WMI leaflets such 
as CMI is to be implemented.24 As these identified consumer 
profiles may not be exhaustive, further quantitative profiling 
of larger consumer populations is required to better discern 
consumer characteristics confounded by different medical 
conditions and medications, alongside other demographic 
factors which may not be represented in this study cohort. 
Such work will be necessary to inform and refine best practice 
approaches to side-effect risk communication in WMI within 
an international context for consumers of both prescription 
and nonprescription medicines.
Conclusion
Three consumer profiles were identified that illustrate how 
consumers appraise medication side-effect risk information. 
Consumers placed specific emphasis on formulating their 
own construct of individual susceptibility to side effects 
when reading side-effect information. Consumers’ interac-
tion with WMI does not lead to a singular way in which 
medicine risks are perceived and interpreted, highlighting 
the need for medicine information writers and/or health 
care professionals to consider furthering the discussion sur-
rounding a more tailored approach to providing side-effect 
information to consumers. Any WMI strategies arising from 
this will require further performance testing to be conducted 
to ensure WMI usability. WMI does not replace spoken 
information, and health care professionals have a key role 
in assisting with the interpretation of side-effect information 
for individuals in their care.
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